Technology

Oyster Point Pharma

$18.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) As of 2:20 PM UTC pre-market

Why Robinhood?

You can buy or sell OYST and other stocks, options, and ETFs commission-free!

About OYST

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. The listed name for OYST is Oyster Point Pharma, Inc. Common Stock.

CEO
Jeffrey A. Nau
Employees
17
Headquarters
Princeton, New Jersey
Founded
2015
Market Cap
454.34M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
125.73K
High Today
$19.62
Low Today
$18.28
Open Price
$19.56
Volume
287.11K
52 Week High
$41.37
52 Week Low
$17.24

Collections

OYST Earnings

-$8.10
-$5.40
-$2.70
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, After Hours

You May Also Like

FDEC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure